Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Indivior Pharmaceuticals Inc. (INDV : NSDQ)

• Company Description    Indivior PLC operates as a specialty pharmaceutical company. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine intoxication and co-occurring conditions, such as schizophrenia. The Company markets and promotes SUBOXONE (buprenorphine and naloxone) Sublingual Film, SUBOXONE (buprenorphine and naloxone) Sublingual Tablet, and SUBUTEX (buprenorphine) Sublingual Tablet, each buprenorphine-based treatment for opioid. Indivior PLC is based in United States. Number of Employees: 838

• Price / Volume Information    Yesterday's Closing Price: $37.53 Daily Weekly Monthly 20 Day Moving Average: 2,496,630 shares Shares Outstanding: 121.92 (millions) Market Capitalization: $4,575.73 (millions) Beta: 0.90 52 Week High: $41.00 52 Week Low: $11.08 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 13.18% 7.65% 12 Week 11.33% 2.92% Year To Date 4.60% -4.01%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 10710 Midlothian Turnpike Suite 125 - North Chesterfield,VA 23235 USA ph: 804-379-1090 fax: 804-379-1215 investorrelations@indivior.com http://www.indivior.com

• General Corporate Information    Officers Joseph Ciaffoni - Chief Executive Officer and Executive Director David Wheadon - Chairman Ryan Preblick - Chief Financial Officer Woodrow Anderson - Senior Vice President Keith Humphreys - Director Peer Information Indivior Pharmaceuticals Inc. (GSAC) Indivior Pharmaceuticals Inc. (CASIF) Indivior Pharmaceuticals Inc. (ALCD.) Indivior Pharmaceuticals Inc. (OMNN) Indivior Pharmaceuticals Inc. (CGPI.) Indivior Pharmaceuticals Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 45579U109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 07/30/26 Share - Related Items Shares Outstanding: 121.92 Most Recent Split Date: (:1) Beta: 0.90 Market Capitalization: $4,575.73 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.81 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $3.35 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 07/30/26

• Fundamental Ratios P/E Current FY Estimate: 11.20 Trailing 12 Months: 12.47 PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: 13.80 Price / Sales: 3.54 EPS Growth vs. Year Ago Period: 134.15% vs. Previous Quarter: 17.07% Sales Growth vs. Year Ago Period: 19.17% vs. Previous Quarter: -11.45% ROE 03/31/26 - -219.26 12/31/25 - -148.76 09/30/25 - -91.71 ROA 03/31/26 - 29.40 12/31/25 - 23.15 09/30/25 - 17.92 Current Ratio 03/31/26 - 0.86 12/31/25 - 0.71 09/30/25 - 0.96 Quick Ratio 03/31/26 - 0.66 12/31/25 - 0.55 09/30/25 - 0.79 Operating Margin 03/31/26 - 29.98 12/31/25 - 25.40 09/30/25 - 21.10 Net Margin 03/31/26 - 19.44 12/31/25 - 16.85 09/30/25 - 9.83 Pre-Tax Margin 03/31/26 - 22.85 12/31/25 - 19.29 09/30/25 - 16.61 Book Value 03/31/26 - -1.18 12/31/25 - -0.78 09/30/25 - - Inventory Turnover 03/31/26 - 1.59 12/31/25 - 1.59 09/30/25 - 1.43 Debt-to-Equity 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Capital 03/31/26 - - 12/31/25 - - 09/30/25 - -

Powered by Zacks Investment Research ©